中性粒细胞与淋巴细胞比值作为醋酸阿比特龙治疗反应预测标志物的回顾性分析:COU302研究
本研究回顾性分析COU302研究,评估基线中性粒细胞与淋巴细胞比值(NLR)对无症状或轻微症状转移性去势抵抗性前列腺癌(mCRPC)患者一线醋酸阿比特龙(AA)联合泼尼松治疗反应的预测价值。结果显示,较高基线NLR与AA治疗组更差的总生存和PSA反应相关,但与安慰剂组无关;治疗期间NLR变化不足以指导治疗。作者认为基线NLR可能预测AA反应,但需进一步验证。
要点
- 较高基线NLR与AA治疗组更差的总生存和PSA反应相关,与安慰剂组无关。
- 基线NLR对影像学进展时间无显著影响。
- 治疗期间NLR变化不足以指导继续AA治疗。
核心结论
- 基线NLR可能预测无症状mCRPC男性对AA的反应,但治疗期间NLR变化不足以指导治疗,需进一步验证研究。
研究设计与样本
- 回顾性分析COU302研究,该研究将无症状或轻微症状mCRPC男性随机分配至一线AA联合泼尼松组或泼尼松组,共1082例患者接受治疗。
主要发现
- 在1082例接受治疗的患者中,基线NLR值除白蛋白外,按基线协变量比较无显著差异。
- 以NLR截断值2.5分组的二分类组间基线变量相似,但NLR<2.5组中骨转移>10处的患者比例较低。
- 较高NLR值对应AA治疗组更差的总生存和PSA反应,而非安慰剂组,此结果在调整回归模型中得到证实。
- 影像学进展时间未见显著差异。
- 治疗基线NLR增加或减少2未能明确提示继续AA治疗缺乏获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为回顾性分析。
- 需进一步验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The neutrophil-lymphocyte ratio (NLR) is an inexpensive and accessible prognostic marker for many cancers, including metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: In this study, we assess the role of NLR as a predictive biomarker through a retrospective analysis of the pivotal COU302 study of abiraterone acetate (AA) as first-line therapy for men with asymptomatic or minimally symptomatic mCRPC. DESIGN, SETTING, AND PARTICIPANTS: The COU302 study randomized asymptomatic or minimally symptomatic men with mCRPC to receive AA plus prednisone or prednisone as first-line treatment. Baseline NLR, overall survival, radiographic progression-free survival, and prostate-specific antigen (PSA) progression-free survival were evaluated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Descriptive statistics, as well as Kaplan-Meier and Cox survival models were used to assess the effect of baseline NLR and changes in NLR on response to AA plus prednisone versus prednisone, with adjustment for important covariates. RESULTS AND LIMITATIONS: Among the 1082 patients who received treatment, baseline NLR values showed no significant differences according to baseline covariates except for albumin. Baseline variables were similar between dichotomous groups with an NLR cutoff of 2.5, except for a lower proportion of patients with >10 bone metastases in the NLR <2.5 group. Our survival results demonstrate that higher NLR values corresponded to poorer overall survival and PSA response to AA but not to placebo, which was confirmed in our adjusted regression models. No significant differences were seen in time to radiographic progression. In separate analyses, an increase or decrease in NLR by 2 from treatment baseline did not clearly signal subsequent lack of benefit with continued AA. CONCLUSIONS: Our results suggest that baseline NLR may be able to predict response to AA in men with asymptomatic mCRPC but that changes in NLR during treatment are insufficient to guide treatment. Further validation studies are warranted. PATIENT SUMMARY: In this report, we look at the ratio of circulating immune cells as a predictor of response to abiraterone acetate (AA), using data from a large trial. Our results suggest that this ratio derived from routinely obtained bloodwork can predict which patients respond better to AA.
引用
- Loubersac T, Nguile-Makao M, Pouliot F, et al. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. Eur Urol Oncol. 2019. PMID: 31411963. doi:10.1016/j.euo.2019.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。